scispace - formally typeset
Search or ask a question
Author

Olivier Meyer

Bio: Olivier Meyer is an academic researcher from Laboratoire de Génie Electrique et Electronique de Paris. The author has contributed to research in topics: Support vector machine & Finite element method. The author has an hindex of 11, co-authored 21 publications receiving 1302 citations. Previous affiliations of Olivier Meyer include Université Paris-Saclay & University of Paris.

Papers
More filters
Journal ArticleDOI
Gerald B. Appel1, Gabriel Contreras2, Mary Anne Dooley3, Ellen M. Ginzler4, David A. Isenberg5, David Jayne6, Lei Shi Li, Eduardo Mysler, Jorge Sánchez-Guerrero, Neil Solomons, David Wofsy7, Carlos Abud, Sharon G. Adler8, Graciela S. Alarcón9, Elisa N. Albuquerque10, Fernando Almeida, Alejandro Alvarellos, Gerald B. Appel1, Hilario Avila11, Cornelia Blume12, Ioannis Boletis, Alain Bonnardeaux, Alan Braun, Jill P. Buyon13, Ricard Cervera14, Nan Chen15, Shun-Le Chen15, António Gomes Da Costa16, Razeen Davids17, David D'Cruz18, Enrique de Ramón, Atul Deodhar19, Andrea Doria20, Bertrand Dussol, Paul Emery21, Justus Fiechtner, Jürgen Floege, Hilda Fragoso-Loyo, Richard Furie22, Rozina Ghazalli23, Cybele Ghossein23, Gary S. Gilkeson24, EM Ginzler25, Caroline Gordon8, Jennifer M. Grossman8, Jieruo Gu26, Loïc Guillevin, Pierre Yves Hatron27, Gisela Herrera28, Falk Hiepe28, Frédéric Houssiau, Osvaldo Hübscher, Claudia Hura29, Joshua Kaplan30, Gianna Mastroianni Kirsztajn30, Emese Kiss31, Ghazali Ahmad Kutty, Maurice Laville, Maria Lazaro, Oliver Lenz2, Leishi Li32, Liz Lightstone33, Sam Lim34, Michel Malaise35, Susan Manzi35, Juan Carlos Marcos, Olivier Meyer36, Pablo Monge37, Saraladev Naicker37, Nathaniel Neal38, Michael Neuwelt39, Kathy Nicholls40, Nancy J. Olsen40, José Ordi-Ros41, Barbara E. Ostrov42, Manuel Pestana43, Michelle Petri44, G. Pokorny44, Jacques Pourrat15, Jiaqi Qian15, Jai Radhakrishnan1, Brad H. Rovin, Julio Sanchez Roman, Joseph C. Shanahan45, William Shergy, Fotini Skopouli, Alberto Spindler46, Christopher Striebich47, Robert Sundel48, Charles R. Swanepoel48, Yen Tan Si49, Guillermo Tate, Vladimír Tesaŕ37, Mohamed Tikly37, Haiyan Wang, Rosnawati Yahya50, Xueqing Yu26, Fengchun Zhang50, Diana Zoruba 
Columbia University1, University of Miami2, University of North Carolina at Chapel Hill3, SUNY Downstate Medical Center4, University College London5, Cambridge University Hospitals NHS Foundation Trust6, University of California, San Francisco7, University of California, Los Angeles8, University of Alabama at Birmingham9, Rio de Janeiro State University10, University of Guadalajara11, University of Düsseldorf12, New York University13, University of Barcelona14, Shanghai Jiao Tong University15, University of Lisbon16, Stellenbosch University17, Guy's and St Thomas' NHS Foundation Trust18, Oregon Health & Science University19, University of Padua20, University of Leeds21, North Shore-LIJ Health System22, Northwestern University23, Medical University of South Carolina24, University of Birmingham25, Sun Yat-sen University26, Lille University of Science and Technology27, Charité28, Rutgers University29, Federal University of São Paulo30, University of Debrecen31, Imperial College London32, Emory University33, University of Liège34, University of Pittsburgh35, University of Paris36, University of the Witwatersrand37, California State University, Long Beach38, Royal Melbourne Hospital39, University of Texas Southwestern Medical Center40, Autonomous University of Barcelona41, Pennsylvania State University42, Johns Hopkins University43, University of Szeged44, Duke University45, University of Colorado Denver46, Harvard University47, University of Cape Town48, University of Malaya49, Peking Union Medical College50
TL;DR: Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Abstract: Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

909 citations

Journal ArticleDOI
01 Mar 2009-Lupus
TL;DR: In this article, the authors report consensus statements that were developed in six important areas: classification of patients with lupus erythematosus, how classification affects the selection of treatment options and definitions of induction, response, flare and maintenance.
Abstract: Systemic lupus erythematosus (SLE) is a complex, multisystem autoimmune disorder, which often involves referral to multiple medical specialists. Lupus nephritis (LN) occurs in ~35% of adults with SLE and predicts poor survival. There is currently no consensus on how to manage patients with SLE or LN across specialties and across different European countries. The Lupus Nephritis Terminology Advisory Group was formed to address this issue as it impacts upon LN treatment. It has developed consensus statements based on opinions from expert panel meetings with nephrologists, nephropathologists, rheumatologists, clinical immunologists and internal medicine specialists from many European countries, after reviewing current guidelines from the European League Against Rheumatism, the American College of Rheumatology and the participants' experience. In this article, we report consensus statements that were developed in six important areas: classification of patients with LN, how classification affects the selection of treatment options and definitions of induction, response, flare and maintenance. We have also proposed a consensus for the terminology involved in the management of LN that is consistent with clinical opinion gathered from multidisciplinary expert meetings and with existing guidelines. We believe this consensus approach provides agreed expert opinion to clinicians and will form the basis for optimising LN treatment.

129 citations

Journal ArticleDOI
TL;DR: The observation of an isoemissive point in the temperature range from -50 degrees C to -110 degrees C in ethanol suggests an interconvertion between two average excited-state populations: unrelaxed and solvent-relaxed CT states and a possible scheme is proposed for the deexcitation pathway, taking into account the kinetics observed in these different solvents.

122 citations

Journal ArticleDOI
TL;DR: The mechanism of the solubilization of egg phosphatidylcholine containing 10% (M/M) of eggosphatidic acid unilamellar vesicles by the nonionic detergent, octyl beta-D-glucopyranoside is investigated at both molecular and supramolecular levels by using fluorescence and turbidity measurements.

91 citations

Journal ArticleDOI
18 Dec 2018
TL;DR: It is shown herein that breast and head phantoms fabricated from 3D-printed structures and liquid mixtures can also accurately mimic most of the head tissues and that, given a binary fluid mixture model, the respective concentrations of the various constituents needed to mimic a particular tissue can be predetermined by means of a standard minimization method.
Abstract: This paper deals with breast and head phantoms fabricated from 3D-printed structures and liquid mixtures whose complex permittivities are close to that of the biological tissues within a large frequency band. The goal is to enable an easy and safe manufacturing of stable-in-time detailed anthropomorphic phantoms dedicated to the test of microwave imaging systems to assess the performances of the latter in realistic configurations before a possible clinical application to breast cancer imaging or brain stroke monitoring. The structure of the breast phantom has already been used by several laboratories to test their measurement systems in the framework of the COST (European Cooperation in Science and Technology) Action TD1301-MiMed. As for the tissue mimicking liquid mixtures, they are based upon Triton X-100 and salted water. It has been proven that such mixtures can dielectrically mimic the various breast tissues. It is shown herein that they can also accurately mimic most of the head tissues and that, given a binary fluid mixture model, the respective concentrations of the various constituents needed to mimic a particular tissue can be predetermined by means of a standard minimization method.

66 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in theUnited States as of April 2011.
Abstract: In the United States, approximately 35% of adults with Systemic Lupus Erythematosus (SLE) have clinical evidence of nephritis at the time of diagnosis; with an estimated total of 50–60% developing nephritis during the first 10 years of disease [1–4]. The prevalence of nephritis is significantly higher in African Americans and Hispanics than in Caucasians, and is higher in men than in women. Renal damage is more likely to develop in non-Caucasian groups [2–4]. Overall survival in patients with SLE is approximately 95% at 5 years after diagnosis and 92% at 10 years [5, 6]. The presence of lupus nephritis significantly reduces survival, to approximately 88% at 10 years, with even lower survival in African Americans [5, 6]. The American College of Rheumatology (ACR) last published guidelines for management of systemic lupus erythematosus (SLE) in 1999 [7]. That publication was designed primarily for education of primary care physicians and recommended therapeutic and management approaches for many manifestations of SLE. Recommendations for management of lupus nephritis (LN) consisted of pulse glucocorticoids followed by high dose daily glucocorticoids in addition to an immunosuppressive medication, with cyclophosphamide viewed as the most effective immunosuppressive medication for diffuse proliferative glomerulonephritis. Mycophenolate mofetil was not yet in use for lupus nephritis and was not mentioned. Since that time, many clinical trials of glucocorticoids-plus-immunosuppressive interventions have been published, some of which are high quality prospective trials, and some not only prospective but also randomized. Thus, the ACR determined that a new set of management recommendations was in order. A combination of extensive literature review and the opinions of highly qualified experts, including rheumatologists, nephrologists and pathologists, has been used to reach the recommendations. The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in the United States as of April 2011. While these recommendations were developed using rigorous methodology, guidelines do have inherent limitations in informing individual patient care; hence the selection of the term “recommendations.” While they should not supplant clinical judgment or limit clinical judgment, they do provide expert advice to the practicing physician managing patients with lupus nephritis.

1,128 citations

Journal ArticleDOI
TL;DR: Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment.
Abstract: Objective To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. Methods Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52. Results Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab (P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo-treated patients and no rituximab-treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti–double-stranded DNA (anti-dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti-dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group. Conclusion Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.

1,073 citations

Journal ArticleDOI
TL;DR: The nature of detergent binding by the membrane from a noncooperative to a cooperative interaction already below the critical micellar concentration is considered and it is concluded that in general binding as a monolayer ring, rather than as a micelle, is the most probable mechanism.

985 citations

Journal ArticleDOI
TL;DR: Recommendations for the management of lupus nephritis were developed using an evidence-based approach followed by expert consensus and there is no evidence to suggest that management of LN should differ in children versus adults.
Abstract: Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN).

849 citations

01 Jan 2012
TL;DR: This chapter discusses general principles in the management of glomerular disease, as well as methods for guideline development and examples of successful implementation of these principles.
Abstract: 142 Summary of Recommendation Statements 143 Chapter 1: Introduction 154 Chapter 2: General principles in the management of glomerular disease 156 Chapter 3: Steroid-sensitive nephrotic syndrome in children 163 Chapter 4: Steroid-resistant nephrotic syndrome in children 172 Chapter 5: Minimal-change disease in adults 177 Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults 181 Chapter 7: Idiopathic membranous nephropathy 186 Chapter 8: Idiopathic membranoproliferative glomerulonephritis 198 Chapter 9: Infection-related glomerulonephritis 200 Chapter 10: Immunoglobulin A nephropathy 209 Chapter 11: Henoch-Schönlein purpura nephritis 218 Chapter 12: Lupus nephritis 221 Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis 233 Chapter 14: Anti-glomerular basement membrane antibody glomerulonephritis 240 Methods for guideline development 243 Biographic and Disclosure Information 252

753 citations